Clinical trials: Acromegaly
Panhypopituitarism, Gigantism/Acromegaly
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood.
- Conditions
- Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
- Trial name
- NCT00001595
- Testing
- Tissue specimen collection, MRI
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Acromegaly, Gigantism
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
The research is aimed at identifying new predisposition genes for endocrine tumours. Our focus initially is on pituitary adenomas including growth hormone-secreting tumors (somatotrophinomas) and prolactin secreting tumours…
- Conditions
- Acromegaly, Gigantism, Familial Isolated Pituitary Adenoma, FIPA
- Trial name
- NCT00461188
- Where
- 3 sites in United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- Barts & The London NHS Trust
Pituitary Diseases, Pituitary Neoplasms
Long Term Outcome Study in Patients With Pituitary Disorders
To determine the outcomes of patients with different pituitary disorders whether they are managed medically, surgically or expectantly.
- Trial name
- NCT03665064
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta
Acromegaly
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00658879
- Testing
- Somavert (Pegvisomant)
- Volunteers
- 251 people
- Sponsor
- Pfizer
Acromegaly
Acromegaly & Sleep Apnoea
Estimates of the prevalence of acromegaly, a condition resulting from excess growth hormone secretion, are as high as 1:1000. If detected late acromegaly increases the risk of joint destruction, heart disease, sleep apnoea, high…
- Trial name
- NCT02371057
- Where
- United Kingdom
- Volunteers
- 653 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Acromegaly
Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
To assess the safety and effectiveness of Somatuline® Depot (lanreotide) Injection when administered by a health care professional (HCP), the patient, the patient's partner or parent/guardian as part of their routine acromegaly…
- Trial name
- SODA (NCT00686348)
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Ipsen
Pituitary Tumor
PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome…
- Trial name
- PITUICARE-Lyon (NCT02854228)
- Where
- France
- Volunteers
- 1,300 people
- Sponsor
- Hospices Civils de Lyon
Acromegaly
Surgical Versus Medical Treatment of Acromegaly
Evaluate biochemical differences in acromegalic patients treated with surgery versus somatostatin analogues (SMS) (after surgery or alone). Hypothesis: Treatment modality exhibit different biochemical responses in acromegaly.
- Trial name
- NCT01000090
- Where
- Denmark
- Volunteers
- 63 people
- Sponsor
- University of Aarhus
Acromegaly
Epidemiology of Acromegaly in Denmark 1991-2010
Aim: To assess the incidence rate, morbidity and mortality of acromegaly in Denmark.
- Trial name
- NCT01752621
- Where
- 2 sites in Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus
Acromegaly, Pituitary Neoplasm
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
The purpose of this study is to compare the efficacy of Sandostatin LAR® (Registered Trademark) Depot to transsphenoidal surgery in previously untreated acromegalic patients with macroadenomas.
- Trial name
- NCT00001860
- Testing
- Sandostatin LAR Depot versus transsphenoidal surgery
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
McCune Albright Syndrome, Polyostotic Fibrous Dysplasia
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
This study will examine the effect of pegvisomant on growth hormone excess in patients with McCune-Albright syndrome (MAS). Patients with this disease have polyostotic fibrous dysplasia-a condition in which areas of normal bone…
- Trial name
- NCT00017927
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)